Dipivefrin

Summary

Dipivefrin (CHEMBL1201262) is an approved small-molecule prodrug (ATC S01EA02); indicated across 1 condition including glaucoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: S01EA02
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 351.4 Da · C19H29NO5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201262
Name	Dipivefrin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3105
ChEBI	CHEBI:4646
ATC	S01EA02
Molecular formula	C19H29NO5
Molecular weight	351.4
InChIKey	OCUJLLGVOUDECM-UHFFFAOYSA-N

SMILES: CC(C)(C)C(=O)OC1=C(C=C(C=C1)C(CNC)O)OC(=O)C(C)(C)C

IUPAC name: [2-(2,2-dimethylpropanoyloxy)-4-[1-hydroxy-2-(methylamino)ethyl]phenyl] 2,2-dimethylpropanoate

ChEBI definition: The dipivalate ester of (±)-epinephrine (racepinephrine). A pro-drug of epinephrine, the hydrochloride is used topically as eye drops to reduce intra-ocular pressure in the treatment of open-angle glaucoma or ocular hypertension.

Pharmacological roles (ChEBI): prodrug, adrenergic agonist, sympathomimetic agent, antiglaucoma drug, ophthalmology drug.

Also known as: Dipivalyl epinephrine, Dipivefrin, Dipivefrina, Dipivefrine, DPE, dipivefrin, DIPIVEFRIN, DIPIVEFRINE, dipivefrine

Parent form; salt/anhydrous children: CHEMBL1200833

Patent coverage: 1,328 distinct patent families (5,099 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 5,082 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
glaucoma	4	MONDO:0005041	MONDO:0005041

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03366935	Not specified	COMPLETED	Combined Implementation of Dural Puncture Epidural and Programmed Intermittent Epidural Bolus for Labor Analgesia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).